HaemaLogiX announces issuance of Japanese patent for KMA.CAR T

HaemaLogiX’s Japanese patent “Kappa Myeloma Antigen Chimeric Receptors and Uses Thereof”  was granted in Japan on 17 February 2023.

The patent covers compositions and methods for treating KMA-expressing malignancies, including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T cells). The patent also covers methods and compositions comprising CAR T cells co-expressing other anti-tumoral agents including cytokines and antibodies.

This patent has also been granted in Australia, USA, and Russia, and is under review in other jurisdictions.